Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 25 entries
Sorted by: Best Match Show Resources per page
Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing .

Open forum infectious diseases

Bassetti M, Vena A, Giacobbe DR, Falcone M, Tiseo G, Giannella M, Pascale R, Meschiari M, Digaetano M, Oliva A, Rovelli C, Carannante N, Losito AR, Carbonara S, Mariani MF, Mastroianni A, Angarano G, Tumbarello M, Tascini C, Grossi P, Mastroianni CM, Mussini C, Viale P, Menichetti F, Viscoli C, Russo A.
PMID: 32462046
Open Forum Infect Dis. 2020 Apr 21;7(5):ofaa139. doi: 10.1093/ofid/ofaa139. eCollection 2020 May.

BACKGROUND: Few data are reported in the literature about the outcome of patients with severe extended-spectrum β-lactamase-producing METHODS: A multicenter retrospective study was performed in Italy (June 2016-June 2019). Successful clinical outcome was defined as complete resolution of clinical...

Cite
Bassetti M, Vena A, Giacobbe DR, et al. Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing . Open Forum Infect Dis. 2020;7(5):ofaa139doi: 10.1093/ofid/ofaa139.
Bassetti, M., Vena, A., Giacobbe, D. R., Falcone, M., Tiseo, G., Giannella, M., Pascale, R., Meschiari, M., Digaetano, M., Oliva, A., Rovelli, C., Carannante, N., Losito, A. R., Carbonara, S., Mariani, M. F., Mastroianni, A., Angarano, G., Tumbarello, M., Tascini, C., Grossi, P., Mastroianni, C. M., Mussini, C., Viale, P., Menichetti, F., Viscoli, C., Russo, A. (2020). Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing . Open forum infectious diseases, 7(5), ofaa139. https://doi.org/10.1093/ofid/ofaa139
Bassetti, Matteo, et al. "Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing ." Open forum infectious diseases vol. 7,5 (2020): ofaa139. doi: https://doi.org/10.1093/ofid/ofaa139
Bassetti M, Vena A, Giacobbe DR, Falcone M, Tiseo G, Giannella M, Pascale R, Meschiari M, Digaetano M, Oliva A, Rovelli C, Carannante N, Losito AR, Carbonara S, Mariani MF, Mastroianni A, Angarano G, Tumbarello M, Tascini C, Grossi P, Mastroianni CM, Mussini C, Viale P, Menichetti F, Viscoli C, Russo A. Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing . Open Forum Infect Dis. 2020 Apr 21;7(5):ofaa139. doi: 10.1093/ofid/ofaa139. eCollection 2020 May. PMID: 32462046; PMCID: PMC7237821.
Copy Download .nbib Format: NLM
A novel .

Neurology. Genetics

Alshaikh JT, Qin K, Zhao L, Mastrianni JA.
PMID: 32637633
Neurol Genet. 2020 Jun 05;6(4):e454. doi: 10.1212/NXG.0000000000000454. eCollection 2020 Aug.

No abstract available.

Cite
Alshaikh JT, Qin K, Zhao L, et al. A novel . Neurol Genet. 2020;6(4):e454doi: 10.1212/NXG.0000000000000454.
Alshaikh, J. T., Qin, K., Zhao, L., & Mastrianni, J. A. (2020). A novel . Neurology. Genetics, 6(4), e454. https://doi.org/10.1212/NXG.0000000000000454
Alshaikh, Jumana T, et al. "A novel ." Neurology. Genetics vol. 6,4 (2020): e454. doi: https://doi.org/10.1212/NXG.0000000000000454
Alshaikh JT, Qin K, Zhao L, Mastrianni JA. A novel . Neurol Genet. 2020 Jun 05;6(4):e454. doi: 10.1212/NXG.0000000000000454. eCollection 2020 Aug. PMID: 32637633; PMCID: PMC7323476.
Copy Download .nbib Format: NLM
Subcutaneous tocilizumab treatment in patients with severe COVID-19-related cytokine release syndrome: An observational cohort study.

EClinicalMedicine

Mastroianni A, Greco S, Apuzzo G, De Santis S, Oriolo C, Zanolini A, Chidichimo L, Vangeli V.
PMID: 32766535
EClinicalMedicine. 2020 Jul 01;24:100410. doi: 10.1016/j.eclinm.2020.100410. eCollection 2020 Jul.

BACKGROUND: Patients with severe coronavirus disease 2019 (COVID-19) have elevated levels of acute phase reactants and inflammatory cytokines, including interleukin-6, indicative of cytokine release syndrome (CRS). The interleukin-6 receptor inhibitor tocilizumab is used for the treatment of chimeric antigen...

Cite
Mastroianni A, Greco S, Apuzzo G, et al. Subcutaneous tocilizumab treatment in patients with severe COVID-19-related cytokine release syndrome: An observational cohort study. EClinicalMedicine. 2020;24:100410doi: 10.1016/j.eclinm.2020.100410.
Mastroianni, A., Greco, S., Apuzzo, G., De Santis, S., Oriolo, C., Zanolini, A., Chidichimo, L., & Vangeli, V. (2020). Subcutaneous tocilizumab treatment in patients with severe COVID-19-related cytokine release syndrome: An observational cohort study. EClinicalMedicine, 24100410. https://doi.org/10.1016/j.eclinm.2020.100410
Mastroianni, Antonio, et al. "Subcutaneous tocilizumab treatment in patients with severe COVID-19-related cytokine release syndrome: An observational cohort study." EClinicalMedicine vol. 24 (2020): 100410. doi: https://doi.org/10.1016/j.eclinm.2020.100410
Mastroianni A, Greco S, Apuzzo G, De Santis S, Oriolo C, Zanolini A, Chidichimo L, Vangeli V. Subcutaneous tocilizumab treatment in patients with severe COVID-19-related cytokine release syndrome: An observational cohort study. EClinicalMedicine. 2020 Jul 01;24:100410. doi: 10.1016/j.eclinm.2020.100410. eCollection 2020 Jul. PMID: 32766535; PMCID: PMC7329292.
Copy Download .nbib Format: NLM
Impaired transmissibility of atypical prions from genetic CJD.

Neurology. Genetics

Cali I, Mikhail F, Qin K, Gregory C, Solanki A, Martinez MC, Zhao L, Appleby B, Gambetti P, Norstrom E, Mastrianni JA.
PMID: 30109268
Neurol Genet. 2018 Aug 07;4(4):e253. doi: 10.1212/NXG.0000000000000253. eCollection 2018 Aug.

OBJECTIVE: To describe the clinicopathologic, molecular, and transmissible characteristics of genetic prion disease in a young man carrying the METHODS: We performed genetic, histologic, and molecular studies, combined with in vivo transmission studies and in vitro replication studies, to...

Cite
Cali I, Mikhail F, Qin K, et al. Impaired transmissibility of atypical prions from genetic CJD. Neurol Genet. 2018;4(4):e253doi: 10.1212/NXG.0000000000000253.
Cali, I., Mikhail, F., Qin, K., Gregory, C., Solanki, A., Martinez, M. C., Zhao, L., Appleby, B., Gambetti, P., Norstrom, E., & Mastrianni, J. A. (2018). Impaired transmissibility of atypical prions from genetic CJD. Neurology. Genetics, 4(4), e253. https://doi.org/10.1212/NXG.0000000000000253
Cali, Ignazio, et al. "Impaired transmissibility of atypical prions from genetic CJD." Neurology. Genetics vol. 4,4 (2018): e253. doi: https://doi.org/10.1212/NXG.0000000000000253
Cali I, Mikhail F, Qin K, Gregory C, Solanki A, Martinez MC, Zhao L, Appleby B, Gambetti P, Norstrom E, Mastrianni JA. Impaired transmissibility of atypical prions from genetic CJD. Neurol Genet. 2018 Aug 07;4(4):e253. doi: 10.1212/NXG.0000000000000253. eCollection 2018 Aug. PMID: 30109268; PMCID: PMC6089695.
Copy Download .nbib Format: NLM
[Septic arthritis in the setting of HIV disease. A case report and literature review].

Le infezioni in medicina

Manfredi R, Legnani G, Mastroianni A, Coronado OV, Chiodo F.
PMID: 12847313
Infez Med. 1997 Mar;5(1):52-6.

A case of septic arthritis due to Haemophilus influenzae is described in a HIV-infected patient. Even though complicated by large effusion and extensive subcutaneous involvement, the clinical picture showed a favourable outcome after prolonged ceftriaxone treatment, leading to complete...

Cite
Manfredi R, Legnani G, Mastroianni A, et al. Artrite settica in corso di infezione da HIV. Presentazione di un caso clinico e rassegna della letteratura. [Septic arthritis in the setting of HIV disease. A case report and literature review]. Infez Med. 1997;5(1):52-6
Manfredi, R., Legnani, G., Mastroianni, A., Coronado, O. V., & Chiodo, F. (1997). Artrite settica in corso di infezione da HIV. Presentazione di un caso clinico e rassegna della letteratura. [Septic arthritis in the setting of HIV disease. A case report and literature review]. Le infezioni in medicina, 5(1), 52-6.
Manfredi, R, et al. "Artrite settica in corso di infezione da HIV. Presentazione di un caso clinico e rassegna della letteratura." [Septic arthritis in the setting of HIV disease. A case report and literature review]. Le infezioni in medicina vol. 5,1 (1997): 52-6.
Manfredi R, Legnani G, Mastroianni A, Coronado OV, Chiodo F. Artrite settica in corso di infezione da HIV. Presentazione di un caso clinico e rassegna della letteratura. [Septic arthritis in the setting of HIV disease. A case report and literature review]. Infez Med. 1997 Mar;5(1):52-6. Italian. PMID: 12847313.
Copy Download .nbib Format: NLM
[Bacteraemia in patients with HIV disease: aetiological spectrum and profile of antimicrobial susceptibility].

Le infezioni in medicina

Manfredi R, Nanetti A, Ferri M, Mastroianni A, Coronado OV, Chiodo F.
PMID: 12847308
Infez Med. 1997 Mar;5(1):23-8.

A retrospective survey of non-opportunistic bacterial pathogens isolated from blood cultures of patients with HIV disease has been carried out for a 6-year period, and the antibiotic susceptibility of the 748 microorganisms cultured from 682 consecutive patients, has been...

Cite
Manfredi R, Nanetti A, Ferri M, et al. Batteriemia in pazienti con infezione da HIV: spettro eziologico e profilo di sensibilità agli agenti antimicrobici. [Bacteraemia in patients with HIV disease: aetiological spectrum and profile of antimicrobial susceptibility]. Infez Med. 1997;5(1):23-8
Manfredi, R., Nanetti, A., Ferri, M., Mastroianni, A., Coronado, O. V., & Chiodo, F. (1997). Batteriemia in pazienti con infezione da HIV: spettro eziologico e profilo di sensibilità agli agenti antimicrobici. [Bacteraemia in patients with HIV disease: aetiological spectrum and profile of antimicrobial susceptibility]. Le infezioni in medicina, 5(1), 23-8.
Manfredi, R, et al. "Batteriemia in pazienti con infezione da HIV: spettro eziologico e profilo di sensibilità agli agenti antimicrobici." [Bacteraemia in patients with HIV disease: aetiological spectrum and profile of antimicrobial susceptibility]. Le infezioni in medicina vol. 5,1 (1997): 23-8.
Manfredi R, Nanetti A, Ferri M, Mastroianni A, Coronado OV, Chiodo F. Batteriemia in pazienti con infezione da HIV: spettro eziologico e profilo di sensibilità agli agenti antimicrobici. [Bacteraemia in patients with HIV disease: aetiological spectrum and profile of antimicrobial susceptibility]. Infez Med. 1997 Mar;5(1):23-8. Italian. PMID: 12847308.
Copy Download .nbib Format: NLM
Early use of canakinumab to prevent mechanical ventilation in select COVID-19 patients: A retrospective, observational analysis.

International journal of immunopathology and pharmacology

Mastroianni A, Greco S, Chidichimo L, Urso F, Greco F, Mauro MV, Vangeli V.
PMID: 34928722
Int J Immunopathol Pharmacol. 2021 Jan-Dec;35:20587384211059675. doi: 10.1177/20587384211059675.

INTRODUCTION: The fully-human monoclonal anti-interleukin (IL)-1β antibody canakinumab may inhibit the production of inflammatory mediators in patients with coronavirus disease 2019 (COVID-19) and the hyperinflammatory response potentially leading to acute respiratory distress syndrome.OBJECTIVES: The goal of our retrospective, observational...

Cite
Mastroianni A, Greco S, Chidichimo L, et al. Early use of canakinumab to prevent mechanical ventilation in select COVID-19 patients: A retrospective, observational analysis. Int J Immunopathol Pharmacol. 2021;35:20587384211059675doi: 10.1177/20587384211059675.
Mastroianni, A., Greco, S., Chidichimo, L., Urso, F., Greco, F., Mauro, M. V., & Vangeli, V. (2021). Early use of canakinumab to prevent mechanical ventilation in select COVID-19 patients: A retrospective, observational analysis. International journal of immunopathology and pharmacology, 3520587384211059675. https://doi.org/10.1177/20587384211059675
Mastroianni, Antonio, et al. "Early use of canakinumab to prevent mechanical ventilation in select COVID-19 patients: A retrospective, observational analysis." International journal of immunopathology and pharmacology vol. 35 (2021): 20587384211059675. doi: https://doi.org/10.1177/20587384211059675
Mastroianni A, Greco S, Chidichimo L, Urso F, Greco F, Mauro MV, Vangeli V. Early use of canakinumab to prevent mechanical ventilation in select COVID-19 patients: A retrospective, observational analysis. Int J Immunopathol Pharmacol. 2021 Jan-Dec;35:20587384211059675. doi: 10.1177/20587384211059675. PMID: 34928722.
Copy Download .nbib Format: NLM
Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repair-Deficient Pancreatic Cancer After Planned Treatment Interruption.

JCO precision oncology

Florou V, Nevala-Plagemann C, Barber KE, Mastroianni JN, Cavalieri CC, Garrido-Laguna I.
PMID: 33542969
JCO Precis Oncol. 2020 Jun 30;4. doi: 10.1200/PO.20.00052. eCollection 2020.

No abstract available.

Cite
Florou V, Nevala-Plagemann C, Barber KE, et al. Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repair-Deficient Pancreatic Cancer After Planned Treatment Interruption. JCO Precis Oncol. 2020;4doi: 10.1200/PO.20.00052.
Florou, V., Nevala-Plagemann, C., Barber, K. E., Mastroianni, J. N., Cavalieri, C. C., & Garrido-Laguna, I. (2020). Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repair-Deficient Pancreatic Cancer After Planned Treatment Interruption. JCO precision oncology, 4. https://doi.org/10.1200/PO.20.00052
Florou, Vaia, et al. "Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repair-Deficient Pancreatic Cancer After Planned Treatment Interruption." JCO precision oncology vol. 4 (2020). doi: https://doi.org/10.1200/PO.20.00052
Florou V, Nevala-Plagemann C, Barber KE, Mastroianni JN, Cavalieri CC, Garrido-Laguna I. Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repair-Deficient Pancreatic Cancer After Planned Treatment Interruption. JCO Precis Oncol. 2020 Jun 30;4. doi: 10.1200/PO.20.00052. eCollection 2020. PMID: 33542969; PMCID: PMC7846057.
Copy Download .nbib Format: NLM
Differential Susceptibility of Bacteria to Mouse Paneth Cell α-Defensins under Anaerobic Conditions.

Antibiotics (Basel, Switzerland)

Mastroianni JR, Lu W, Selsted ME, Ouellette AJ.
PMID: 25383215
Antibiotics (Basel). 2014;3(4):493-508. doi: 10.3390/antibiotics3040493.

Small intestinal Paneth cells secrete α-defensin peptides, termed cryptdins (Crps) in mice, into the intestinal lumen, where they confer immunity to oral infections and define the composition of the ileal microbiota. In these studies, facultative bacteria maintained under aerobic...

Cite
Mastroianni JR, Lu W, Selsted ME, et al. Differential Susceptibility of Bacteria to Mouse Paneth Cell α-Defensins under Anaerobic Conditions. Antibiotics (Basel). 2014;3(4):493-508doi: 10.3390/antibiotics3040493.
Mastroianni, J. R., Lu, W., Selsted, M. E., & Ouellette, A. J. (2014). Differential Susceptibility of Bacteria to Mouse Paneth Cell α-Defensins under Anaerobic Conditions. Antibiotics (Basel, Switzerland), 3(4), 493-508. https://doi.org/10.3390/antibiotics3040493
Mastroianni, Jennifer R, et al. "Differential Susceptibility of Bacteria to Mouse Paneth Cell α-Defensins under Anaerobic Conditions." Antibiotics (Basel, Switzerland) vol. 3,4 (2014): 493-508. doi: https://doi.org/10.3390/antibiotics3040493
Mastroianni JR, Lu W, Selsted ME, Ouellette AJ. Differential Susceptibility of Bacteria to Mouse Paneth Cell α-Defensins under Anaerobic Conditions. Antibiotics (Basel). 2014;3(4):493-508. doi: 10.3390/antibiotics3040493. PMID: 25383215; PMCID: PMC4220453.
Copy Download .nbib Format: NLM
Ochrobactrum anthropi bacteremia: case report and review of the literature.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Mastroianni A, Cancellieri C, Montini G.
PMID: 11851711
Clin Microbiol Infect. 1999 Sep;5(9):570-573. doi: 10.1111/j.1469-0691.1999.tb00437.x.

No abstract available.

Cite
Mastroianni A, Cancellieri C, Montini G. Ochrobactrum anthropi bacteremia: case report and review of the literature. Clin Microbiol Infect. 1999;5(9):570-573doi: 10.1111/j.1469-0691.1999.tb00437.x.
Mastroianni, A., Cancellieri, C., & Montini, G. (1999). Ochrobactrum anthropi bacteremia: case report and review of the literature. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 5(9), 570-573. https://doi.org/10.1111/j.1469-0691.1999.tb00437.x
Mastroianni, Antonio, et al. "Ochrobactrum anthropi bacteremia: case report and review of the literature." Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases vol. 5,9 (1999): 570-573. doi: https://doi.org/10.1111/j.1469-0691.1999.tb00437.x
Mastroianni A, Cancellieri C, Montini G. Ochrobactrum anthropi bacteremia: case report and review of the literature. Clin Microbiol Infect. 1999 Sep;5(9):570-573. doi: 10.1111/j.1469-0691.1999.tb00437.x. PMID: 11851711.
Copy Download .nbib Format: NLM
Early Delivery of Misfolded PrP from ER to Lysosomes by Autophagy.

International journal of cell biology

Cortes CJ, Qin K, Norstrom EM, Green WN, Bindokas VP, Mastrianni JA.
PMID: 24454378
Int J Cell Biol. 2013;2013:560421. doi: 10.1155/2013/560421. Epub 2013 Dec 17.

Prion diseases are linked to the accumulation of a misfolded isoform (PrP(Sc)) of prion protein (PrP). Evidence suggests that lysosomes are degradation endpoints and sites of the accumulation of PrP(Sc). We questioned whether lysosomes participate in the early quality...

Cite
Cortes CJ, Qin K, Norstrom EM, et al. Early Delivery of Misfolded PrP from ER to Lysosomes by Autophagy. Int J Cell Biol. 2013;2013:560421doi: 10.1155/2013/560421.
Cortes, C. J., Qin, K., Norstrom, E. M., Green, W. N., Bindokas, V. P., & Mastrianni, J. A. (2013). Early Delivery of Misfolded PrP from ER to Lysosomes by Autophagy. International journal of cell biology, 2013560421. https://doi.org/10.1155/2013/560421
Cortes, Constanza J, et al. "Early Delivery of Misfolded PrP from ER to Lysosomes by Autophagy." International journal of cell biology vol. 2013 (2013): 560421. doi: https://doi.org/10.1155/2013/560421
Cortes CJ, Qin K, Norstrom EM, Green WN, Bindokas VP, Mastrianni JA. Early Delivery of Misfolded PrP from ER to Lysosomes by Autophagy. Int J Cell Biol. 2013;2013:560421. doi: 10.1155/2013/560421. Epub 2013 Dec 17. PMID: 24454378; PMCID: PMC3877647.
Copy Download .nbib Format: NLM
Correction for Cobo et al., "Entamoeba histolytica Alters Ileal Paneth Cell Functions in Intact and Muc2 Mucin Deficiency".

Infection and immunity

Cobo ER, Holani R, Moreau F, Nakamura K, Ayabe T, Mastroianni JR, Eriguchi Y, Ouellette A, Chadee K.
PMID: 30242014
Infect Immun. 2018 Sep 21;86(10). doi: 10.1128/IAI.00564-18. Print 2018 Oct.

No abstract available.

Cite
Cobo ER, Holani R, Moreau F, et al. Correction for Cobo et al., "Entamoeba histolytica Alters Ileal Paneth Cell Functions in Intact and Muc2 Mucin Deficiency". Infect Immun. 2018;86(10)doi: 10.1128/IAI.00564-18.
Cobo, E. R., Holani, R., Moreau, F., Nakamura, K., Ayabe, T., Mastroianni, J. R., Eriguchi, Y., Ouellette, A., & Chadee, K. (2018). Correction for Cobo et al., "Entamoeba histolytica Alters Ileal Paneth Cell Functions in Intact and Muc2 Mucin Deficiency". Infection and immunity, 86(10), . https://doi.org/10.1128/IAI.00564-18
Cobo, Eduardo R, et al. "Correction for Cobo et al., "Entamoeba histolytica Alters Ileal Paneth Cell Functions in Intact and Muc2 Mucin Deficiency"." Infection and immunity vol. 86,10 (2018). doi: https://doi.org/10.1128/IAI.00564-18
Cobo ER, Holani R, Moreau F, Nakamura K, Ayabe T, Mastroianni JR, Eriguchi Y, Ouellette A, Chadee K. Correction for Cobo et al., "Entamoeba histolytica Alters Ileal Paneth Cell Functions in Intact and Muc2 Mucin Deficiency". Infect Immun. 2018 Sep 21;86(10). doi: 10.1128/IAI.00564-18. Print 2018 Oct. PMID: 30242014; PMCID: PMC6204739.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 25 entries